Table 1.
Baseline clinical characteristics of patients
| Serum hs‐CRP, mg/L | |||||
|---|---|---|---|---|---|
| Characteristics | Q1 (n = 453) | Q2 (n = 449) | Q3 (n = 451) | Q4 (n = 451) | p‐Value |
| Age (years) | 59 (51–66) | 58 (50–66) | 59 (50–67) | 60 (50–67) | .352 |
| Male sex, n (%) | 368 (81.2) | 358 (79.7) | 355 (78.7) | 367 (81.4) | .709 |
| BMI (kg/m2) | 25.5 (23.6–27.7) | 26.1 (24.0–28.4) | 26.0 (24.1–28.4) | 25.9 (23.7–30.5) | .018 |
| Systolic BP (mmHg) | 126 (117–135) | 125 (117–135) | 125 (114–136) | 122 (110–142) | .023 |
| Diastolic BP (mmHg) | 75 (70–81) | 75 (70–80) | 76 (69–84) | 72 (68–80) | .043 |
| Heart rate (bpm) | 70 (65–77) | 70 (65–77) | 71 (66–80) | 72 (66–84) | <.001 |
| Hypertension, n (%) | 260 (57.4) | 282 (62.8) | 281 (62.3) | 263 (58.3) | .234 |
| Diabetes, n (%) | 136 (30.0) | 148 (33.0) | 144 (31.9) | 135 (29.9) | .708 |
| Dyslipidemia, n (%) | 208 (45.9) | 207 (46.1) | 199 (44.1) | 198 (43.9) | .155 |
| Previous or current smoking, n (%) | 278 (61.4) | 264 (58.8) | 281 (62.3) | 287 (63.6) | .497 |
| Previous MI, n (%) | 78 (17.2) | 62 (13.8) | 69 (15.3) | 69 (15.3) | .566 |
| Previous PCI, n (%) | 40 (8.8) | 31 (6.9) | 31 (6.9) | 38 (8.4) | .581 |
| Previous CABG, n (%) | 4 (0.9) | 4 (0.9) | 6 (1.3) | 8 (1.8) | .567 |
| Previous stroke, n (%) | 48 (10.6) | 54 (12.0) | 36 (8.0) | 57 (12.6) | .114 |
| LVEF (%) | 60 (54–65) | 59 (53–63) | 58 (52–63) | 55 (49–66) | <.001 |
| Grace score | 108 (92–125) | 109 (91–128) | 114 (98–130) | 120 (102–141) | <.001 |
| Laboratory values at hospital admission | |||||
| WBC count (×109/L) | 7.20 (6.07–8.78) | 7.75 (6.53–9.54) | 8.06 (6.64–10.02) | 8.85 (7.18–10.59) | <.001 |
| Hemoglobin (g/L) | 146 (136–156) | 147 (135–156) | 143 (132–152) | 142 (129–152) | <.001 |
| Platelet count (×109/L) | 222 (186–260) | 228 (189–270) | 236 (190–279) | 224 (185–268) | .014 |
| SCr (mmol/L) | 72.90 (63.90–83.85) | 74.30 (65.00–85.45) | 74.50 (64.20–85.70) | 76.40 (65.30–89.70) | .014 |
| eGFR (ml/min) | 97.05 (87.84–104.92) | 97.07 (85.96–106.15) | 97.28 (86.43–105.26) | 95.68 (82.05–105.04) | .264 |
| Uric acid (umol/L) | 341.40 (286.95–402.65) | 354.80 (294.50–419.85) | 351.30 (294.40–427.00) | 359.30 (296.00–420.90) | .058 |
| FBG (mmol/L) | 6.25 (5.31–8.25) | 6.47 (5.47–8.57) | 6.47 (5.51–8.81) | 6.80 (5.54–9.36) | .003 |
| HbA1c (%) | 6.00 (5.60–7.20) | 6.00 (5.60–7.40) | 6.10 (5.70–7.30) | 6.10 (5.60–7.40) | .258 |
| TC (mmol/L) | 3.87 (3.19–4.61) | 4.12 (3.49–4.93) | 4.13 (3.54–4.92) | 4.35 (3.63–5.11) | <.001 |
| TG (mmol/L) | 1.39 (0.98–1.93) | 1.63 (1.20–2.27) | 1.53 (1.13–2.16) | 1.52 (1.14–2.20) | <.001 |
| LDL‐C (mmol/L) | 2.24 (1.74–2.89) | 2.46 (1.95–3.12) | 2.55 (2.05–3.19) | 2.77 (2.17–3.34) | <.001 |
| HDL‐C (mmol/L) | 1.02 (0.88–1.18) | 0.97 (0.83–1.12) | 0.93 (0.82–1.09) | 0.94 (0.82–1.08) | <.001 |
| CK‐MB (ng/L) | 1.90 (1.20–9.95) | 2.70 (1.40–30.05) | 3.60 (1.50–78.50) | 10.40 (2.10–99.30) | <.001 |
| hs‐TnI (ng/L) | 0.12 (0.10–1.35) | 0.43 (0.05–3.28) | 1.05 (0.12–8.44) | 4.21 (0.52–17.12) | <.001 |
| Lesion charateristic | |||||
| LM disease | 35 (7.7) | 28 (6.2) | 31 (6.9) | 34 (7.5) | .815 |
| One‐vessel disease, n (%) | 114 (25.2) | 108 (24.1) | 106 (23.5) | 104 (23.1) | .893 |
| Two‐vessel disease, n (%) | 149 (32.9) | 168 (37.4) | 155 (34.4) | 147 (32.6) | .405 |
| Three‐vessel disease, n (%) | 185 (40.8) | 171 (38.1) | 185 (41.0) | 196 (43.5) | .441 |
| Target vessel territory | |||||
| LAD, n (%) | 237 (52.3) | 213 (47.4) | 226 (50.1) | 235 (52.1) | .428 |
| LCX, n (%) | 101 (22.3) | 120 (26.7) | 115 (25.5) | 130 (28.8) | .152 |
| RCA, n (%) | 173 (38.2) | 185 (41.2) | 171 (37.9) | 146 (32.4) | .050 |
| Clinical diagnosis | |||||
| STEMI, n (%) | 223 (49.2) | 235 (52.3) | 232 (51.4) | 254 (56.3) | .190 |
| NSTEMI, n (%) | 230 (50.8) | 214 (47.7) | 219 (48.6) | 197 (43.7) | .190 |
| Medications in hospital | |||||
| Aspirin, n (%) | 452 (99.8) | 447 (99.6) | 449 (99.6) | 451 (100) | .529 |
| Clopidogrel/ticagrelor, n (%) | 452 (99.8) | 447 (99.6) | 449 (99.6) | 450 (99.8) | .878 |
| Statin, n (%) | 452 (99.8) | 449 (100) | 451 (100) | 450 (99.8) | .574 |
| ACEI/ARB, n (%) | 192 (42.4) | 193 (43.0) | 205 (45.5) | 222 (49.2) | .153 |
| β‐Blockers, n (%) | 358 (79.0) | 337 (75.1) | 348 (77.2) | 368 (81.6) | .106 |
| CCB, n (%) | 68 (15.0) | 68 (15.1) | 63 (14.0) | 47 (10.4) | .133 |
| Nitrate, n (%) | 418 (92.3) | 407 (90.6) | 416 (92.2) | 410 (90.9) | .731 |
| IIbIIIA, n (%) | 52 (11.5) | 59 (13.1) | 60 (13.3) | 83 (18.4) | .018 |
Note: Values are presented as the mean ± SD, median (IQR), or number (%).
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass grafting; CCB, calcium channel blockers; CK‐MB, creatine kinase isoenzyme‐MB; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; Grace, Global Registry of Acute Coronary Events; HbA1c, glycosylated hemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; hs‐CRP, high‐sensitivity C‐reactive protein; hs‐TnI, high sensitive troponin I; IIbIIIA, IIBbIIIA receptor antagonist; IQR, interquartile range; LAD, left anterior descending artery; LCX, left circumflex artery; LDL‐C, low‐density lipoprotein cholesterol; LM, left main; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSTEMI, non ST‐segment elevation myocardial infarction; PCI, percutaneous coronary intervention; RCA, right coronary artery; SCr, serum creatinine; STEMI, ST‐segment elevation myocardial infarction; TC, total cholesterol; TG, triglycerides; WBC, white blood cell.